Global Oral Contraceptive Pills Market by Type (Combined Oral Contraceptives, Progestin-Only Pills), by Application (Family Planning, Hormonal Therapy), by End-Use Industry (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Oral Contraceptive Pills Market was valued at USD 7.0 Billion in 2024-e and will surpass USD 10.7 Billion by 2030; growing at a CAGR of 7.3% during 2025 - 2030.

The Oral Contraceptive Pills Market is witnessing steady growth as women increasingly seek convenient and effective birth control options. Oral contraceptives, including combined oral contraceptives (COCs) and progestin-only pills (POPs), are among the most widely used methods of contraception, offering ease of use, reliability, and hormonal regulation. As the global demand for family planning and hormonal therapy continues to rise, the market for oral contraceptive pills is expanding across various regions. With advances in formulations and increased awareness about reproductive health, the market is poised for continued growth.

Combined Oral Contraceptives Segment Is Largest Owing to Broad Usage and Effectiveness

The combined oral contraceptives (COCs) segment is the largest within the oral contraceptive pills market, largely due to their widespread use and effectiveness. COCs contain both estrogen and progestin, which work together to prevent ovulation, thicken cervical mucus, and alter the uterine lining, providing comprehensive birth control. This method is popular for its reliability and the added benefit of regulating menstrual cycles, making it a preferred choice for many women.

COCs also offer additional therapeutic benefits, such as managing acne and reducing the risk of ovarian cysts, which further contribute to their widespread use. As a result, combined oral contraceptives remain the most widely prescribed and dominant segment in the market, especially among women seeking both contraceptive and non-contraceptive health benefits.

Progestin-Only Pills Segment Is Fastest Growing Owing to Suitability for Specific Health Needs

The progestin-only pills (POPs) segment is the fastest-growing in the oral contraceptive pills market, as these pills provide a suitable option for women who cannot use estrogen-based contraceptives. Progestin-only pills are ideal for breastfeeding women, those who experience side effects from estrogen, or individuals with certain health conditions such as hypertension or a history of blood clots.

The increasing demand for POPs is also driven by the growing awareness of alternative contraceptive options and the focus on personalized healthcare solutions. As more women seek customized contraception that aligns with their individual health needs, the popularity of progestin-only pills is growing, making it the fastest-expanding segment within the market.

Family Planning Segment Is Largest Application Owing to Global Demand for Birth Control

The family planning application segment is the largest in the oral contraceptive pills market, as the primary purpose of oral contraceptives is to prevent unwanted pregnancies. Family planning remains a critical issue globally, with women seeking reliable and accessible methods to control reproduction and plan their families. Oral contraceptives provide a practical and effective solution for family planning, enabling women to delay or prevent pregnancy according to their personal and social circumstances.

The rising awareness of reproductive health, along with government initiatives promoting family planning, particularly in developing regions, continues to drive demand for oral contraceptive pills. As family planning remains a central concern, this application segment holds the largest share in the overall market.

Retail Pharmacies Segment Is Largest End-Use Industry Owing to Widespread Accessibility

Retail pharmacies represent the largest end-use industry in the oral contraceptive pills market due to their widespread accessibility to consumers. Pharmacies are a convenient point of purchase for oral contraceptives, providing women with easy access to contraception, either through prescriptions or over-the-counter options in some regions.

The ability to easily purchase oral contraceptive pills from retail pharmacies, combined with the growing preference for self-management of contraception, makes this segment the largest. Additionally, retail pharmacies are a key part of the distribution network, ensuring the availability of various contraceptive pill options for consumers across different demographics.

North America Is Largest Region Owing to High Awareness and Healthcare Access

North America is the largest region in the oral contraceptive pills market, driven by high awareness of reproductive health, widespread access to healthcare services, and the availability of a variety of contraceptive options. In particular, the United States has a well-established healthcare system, with many women having easy access to contraception through healthcare providers, pharmacies, and online platforms.

The region’s focus on sexual health education, along with the increasing demand for family planning and hormone-based therapies, fuels the continued growth of the market. With greater access to contraceptive pills and an increasing number of women seeking reproductive health solutions, North America remains the dominant region in this market.

Competitive Landscape and Key Players

The Oral Contraceptive Pills Market is highly competitive, with key players such as Pfizer, Bayer AG, Johnson & Johnson, and Mylan N.V. leading the industry. These companies offer a wide range of oral contraceptive pills, including both combined oral contraceptives and progestin-only pills, catering to different consumer needs.

The competitive landscape is characterized by continuous product innovation, with companies developing new formulations to address specific health concerns such as acne, menstrual disorders, and fertility regulation. Market leaders are also expanding their presence in emerging markets and strengthening their portfolios through strategic partnerships, acquisitions, and enhanced distribution networks. These efforts aim to capture a larger share of the growing demand for oral contraceptives worldwide.

Recent Developments:

• Bayer AG launched a new low-dose oral contraceptive pill aimed at minimizing side effects while maintaining efficacy.
• Pfizer Inc. introduced a new line of emergency contraceptive pills, now available over-the-counter in several regions.
• Mylan N.V. partnered with a major retail pharmacy chain to distribute its generic oral contraceptive pills in key global markets.
• Merck & Co., Inc. expanded its product portfolio by introducing a new oral contraceptive specifically designed for women with hormonal imbalances.
• Teva Pharmaceutical Industries Ltd. acquired a competitor in the oral contraceptive market, strengthening its position in the global reproductive health space.

List of Leading Companies:

• Bayer AG
• Pfizer Inc.
• Johnson & Johnson
• Mylan N.V.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• HLL Lifecare Limited
• Lupin Pharmaceuticals
• Cipla Limited
• Glenmark Pharmaceuticals
• Abbott Laboratories
• Aurobindo Pharma
• Alvogen
• Sun Pharmaceutical Industries
• Amgen Inc.

Report Scope: